Fred E. Cohen
Fred E. Cohen's purchase track record
Fred E. Cohen has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/5/2026 | NTLA | $1.40M | +41.9% | +90.4% | +9.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Intellia Therapeutics Appoints New Chief Medical Officer. Intellia Therapeutics announced the appointment of Jing L. Marantz as its new Chief Medical Officer. This leadership change occurred as the stock recently rose 7.6%, moving away from recent support levels. The news highlights a strategic shift in the company's medical leadership during a period of increased market activity.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Kyverna Reports Positive One-Year Data for Miv-cel Trials. Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Progyny (PGNY) shares rise over 6% amid record sales pace. Shares of Progyny jumped about 6% after the company reported a selling season that is pacing toward a record level. Analysts noted the move while also comparing the stock’s valuation to peers such as CRL. The price action comes as the stock trades with an RSI near 61 and holds above a support level around $25.40. The news adds to recent discussion about potential upside, though the stock remains below its 52‑week high.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
UroGen Pharma highlighted as emerging GARP stock. UroGen Pharma is being discussed as an emerging GARP stock, indicating growing interest from analysts. The average target price of $60.00, with a range of $48.00 to $75.00, suggests potential upside from its current level. The stock trades near its 12‑touch support at $40.15 and has a moderate RSI of 35.3, indicating it is not overbought. These factors may influence how investors view its future performance.
Transaction History
| CDNA | ▲ Buy | Grant | 9,795 | $0 | 6/12/2026 | View on chart |
| NTLA | ▲ Buy | Grant | 9,200 | $0 | 6/9/2026 | View on chart |
| KYTX | ▲ Buy | Grant | 5,093 | $0 | 5/27/2026 | View on chart |
| NTLA | ▲ Buy | Open Market | 150,000 | $1.4M | 1/5/2026 | View on chart |
| CDNA | ▲ Buy | Grant | 12,103 | $0 | 6/13/2025 | View on chart |
| NTLA | ▲ Buy | Grant | 8,000 | $0 | 6/11/2025 | View on chart |
| KYTX | ▲ Buy | Grant | 16,634 | $0 | 5/29/2025 | View on chart |
| CDNA | ▲ Buy | Grant | 10,570 | $0 | 6/14/2024 | View on chart |
| NTLA | ▲ Buy | Grant | 7,737 | $0 | 6/12/2024 | View on chart |
| PGNY | ▲ Buy | Grant | 6,176 | $0 | 5/23/2024 | View on chart |
| KYTX | ▼ Sell | Other | 4,523,924 | — | 2/12/2024 | View on chart |
| URGN | ▲ Buy | Grant | 69,339 | $661K | 7/26/2023 | View on chart |
| CDNA | ▲ Buy | Grant | 18,844 | $0 | 6/16/2023 | View on chart |
| NTLA | ▲ Buy | Grant | 4,425 | $0 | 6/14/2023 | View on chart |
| PGNY | ▲ Buy | Grant | 4,385 | $0 | 5/24/2023 | View on chart |
| CDNA | ▲ Buy | Grant | 1,062 | $0 | 1/6/2023 | View on chart |
| PGNY | ▲ Buy | Grant | 3,480 | $0 | 10/24/2022 | View on chart |
| CDNA | ▲ Buy | Grant | 803 | $0 | 10/4/2022 | View on chart |
| CDNA | ▲ Buy | Grant | 4,863 | $0 | 6/16/2022 | View on chart |
| NTLA | ▲ Buy | Grant | 5,197 | $0 | 6/14/2022 | View on chart |
| PGNY | ▲ Buy | Grant | 2,652 | $0 | 10/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
CareDx shows high growth and fair‑value boost after reimbursement news
Recent coverage noted CareDx’s strong revenue growth and improving fundamentals. Analyst updates cited new reimbursement information and target revisions, leading to a modest fair‑value increase. The company’s performance appears to be gaining attention among investors.
CareDx shows high growth and fair‑value boost after reimbursement news. Recent coverage noted CareDx’s strong revenue growth and improving fundamentals. Analyst updates cited new reimbursement information and target revisions, leading to a modest fair‑value increase. The company’s performance appears to be gaining attention among investors.